Lite Strategy, Inc. — fact timeline

Tamar D. Howson departed as Director at Lite Strategy, Inc..

“Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.”

Stéphane Peluso was appointed as Chief Scientific Officer at Lite Strategy, Inc..

“Stéphane Peluso will become Chief Scientific Officer”

Robert Ilaria Jr. was appointed as Chief Medical Officer at Lite Strategy, Inc..

“Robert Ilaria Jr. will become Chief Medical Officer”

David M. Urso changed role as Chief Executive Officer at Lite Strategy, Inc..

“David M. Urso will become Chief Executive Officer.”

Daniel Gold departed as Director at Lite Strategy, Inc..

“Daniel Gold, Ph.D. will resign as Chief Executive Officer.”

Lite Strategy, Inc. reported second quarter ended December 31, 2022 results: revenue $32.7 million, net income $10.3 million, EPS $0.08 per share.

“• MEI recognized revenue of $32.7 million for the quarter ended December 31, 2022, compared to $11.8 million for the quarter ended December 31, 2021. As a result of the discontinuation of the zandelisib program, we updated our estimated costs to complete each development performance obligation under the license agreement with Kyowa Kirin. This resulted in a higher progress towards completion and revenue for performance obligations that will not commence. • Net income was $10.3 million, or $0.08 per share, for the quarter ended December 31, 2022, compared to net loss of $12.2 million, or $0.10 per share for the quarter ended December 31, 2021.”

Lite Strategy, Inc. shareholders approved Ratification of Appointment of BDO USA, LLP at the 2023-01-05 meeting.

“Proposal 5. – Ratification of Appointment of BDO USA, LLP. Proposal 5 was to ratify the appointment of BDO USA, LLP, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending June 30, 2023. The proposal was approved. For Against Abstain 78,700,571 689,734 5,192,069”

Lite Strategy, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-01-05 meeting.

“Proposal 4. – Advisory Vote on Executive Compensation. Proposal 4 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. For Against Abstain Broker Non- Votes 43,376,299 6,778,476 4,147,548 30,280,051”

Lite Strategy, Inc. shareholders approved Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split at the 2023-01-05 meeting.

“Proposal 3. – Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split. Proposal 3 was to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-10 and 1-for-20, at any time prior to June 30, 2023, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of the Company’s stockholders. The proposal was approved. For Against Abstain 68,495,443 12,271,441 3,815,490”

Lite Strategy, Inc. shareholders approved Approval of Amended and Restated 2008 Stock Omnibus Equity Compensation Plan at the 2023-01-05 meeting.

“Proposal 2. – Approval of Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. Proposal 2 was to approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan (the “2008 Equity Plan”) to increase the number of shares of common stock that may be subject to awards and to make certain other changes to the plan terms included in the plan document attached as Annex A to the definitive proxy statement relating to the Annual Meeting. The proposal was approved. For Against Abstain Broker Non- Votes 44,169,994 5,892,604 4,239,725 30,280,051”

Lite Strategy, Inc. shareholders approved Election of Director at the 2023-01-05 meeting.

“Proposal 1. – Election of Director. The following individual, who was named as a nominee in the Company’s definitive proxy statement relating to the Annual Meeting, was elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors which will expire at the Company’s annual meeting of stockholders for fiscal year 2026. Information on the vote relating to the director standing for election is set forth below: Nominee For Withheld Broker Non- Votes Dr. Thomas C. Reynolds 49,024,478 5,277,845 30,280,051”

Cheryl L. Cohen departed as Director at Lite Strategy, Inc..

“On October 4, 2022, Cheryl L. Cohen, a member of the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) and member of the Audit Committee of the Board (the “Committee”), informed the Company that she has decided not to stand for reelection at the Company’s fiscal year 2023 annual meeting of stockholders (the “Annual Meeting”).”

Dr. Christine A. White departed as Chair and member of the Board of Directors at Lite Strategy, Inc..

“Dr. Christine A. White, Chair and member of the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) and member of the Nominating and Corporate Governance Committee of the Board (the “Committee”), informed the Company that, after more than 12 years of service, she has decided to formally retire and thus she does not intend to stand for reelection at the Company’s fiscal year 2023 annual meeting of stockholders (the “Annual Meeting”).”

Brian G. Drazba departed as Chief Financial Officer at Lite Strategy, Inc..

“On December 21, 2021, Mr. Drazba and the Company mutually agreed to extend the term of Mr. Drazba’s employment to June 30, 2022 (or an earlier date determined by either party), pursuant to a letter agreement dated December 21, 2021 (the “Letter Agreement”).”

Sujay Kango was appointed as Director at Lite Strategy, Inc..

“On November 22, 2021, the Board appointed Mr. Sujay Kango to fill the vacancy on the Board resulting from the vacancy created by the resignation of Mr. Clemens.”

Kevan Clemens resigned as Director at Lite Strategy, Inc..

“On November 22, 2021, Mr. Kevan Clemens, a member of the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) resigned from the Board, effective immediately.”

Brian G. Drazba departed as Chief Financial Officer and Secretary at Lite Strategy, Inc..

“On August 2, 2021, Brian G. Drazba, the Chief Financial Officer and Secretary of MEI Pharma, Inc. (the “Company”), and the Company mutually agreed that Mr. Drazba will retire from the Company, effective December 31, 2021.”